Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study

A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

NCT00289016 ·Status: COMPLETED ·Phase: PHASE2

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

NCT01654692 ·Status: COMPLETED ·Phase: PHASE2

A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma

NCT03696069 ·Status: COMPLETED

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis

NCT06400550 ·Status: RECRUITING

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

NCT01340729 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

NCT00790010 ·Status: COMPLETED ·Phase: PHASE1

Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis

NCT07256184 ·Status: COMPLETED

Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary

NCT02828202 ·Status: RECRUITING

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162 ·Status: TERMINATED ·Phase: PHASE2

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

NCT05578872 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Immune Monitoring in Metastatic Melanoma

NCT04158544 ·Status: UNKNOWN

Ipilimumab + Temozolomide in Metastatic Melanoma

NCT01119508 ·Status: COMPLETED ·Phase: PHASE2

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

NCT02009397 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

NCT05115006 ·Status: COMPLETED

Use of 852A in Metastatic Cutaneous Melanoma.

NCT00189332 ·Status: COMPLETED ·Phase: PHASE2

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

NCT04197882 ·Status: UNKNOWN ·Phase: PHASE1

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

NCT00803374 ·Status: WITHDRAWN ·Phase: PHASE1

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872 ·Status: COMPLETED ·Phase: PHASE2

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

NCT04356729 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

NCT00040352 ·Status: RECRUITING

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice

NCT05402059 ·Status: UNKNOWN

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

NCT03190824 ·Status: UNKNOWN ·Phase: PHASE2

Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1

NCT07040436 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Treatment Use Study for Advanced Melanoma.

NCT00584493 ·Status: NO_LONGER_AVAILABLE